Cargando…

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma

BACKGROUND: Pancreatic cancer is expected to be the third deadliest cancer in the US in 2021. Evaluation of treatment response in patients with mPDAC necessitates scheduled clinical and radiographic assessments along with monitoring serum CA 19-9 levels. Currently available single-institution data e...

Descripción completa

Detalles Bibliográficos
Autores principales:	George, Ben, Kent, Matthew, Surinach, Andy, Lamarre, Neil, Cockrum, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522478/ https://www.ncbi.nlm.nih.gov/pubmed/34671563 http://dx.doi.org/10.3389/fonc.2021.754687

Ejemplares similares

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2021)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
por: Elias, Rawad, et al.
Publicado: (2022)

Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
por: Koeller, Jim, et al.
Publicado: (2020)

Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States
por: Paluri, Ravi, et al.
Publicado: (2022)

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes
por: O'Reilly, Eileen M., et al.
Publicado: (2020)

How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
por: Pretta, Andrea, et al.
Publicado: (2022)

Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
por: Varzaru, Bianca, et al.
Publicado: (2023)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
por: Yu, Kenneth H., et al.
Publicado: (2021)

Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma
por: Ermiah, Eramah, et al.
Publicado: (2022)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data
por: Bengtsson, Axel, et al.
Publicado: (2020)

Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
por: Nurmi, Anna M., et al.
Publicado: (2021)

Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma
por: Stuhr, Liva K., et al.
Publicado: (2023)

The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
por: Houg, Demi S., et al.
Publicado: (2018)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
por: Taieb, Julien, et al.
Publicado: (2023)

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
por: Gautam, Shailendra K., et al.
Publicado: (2023)

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
por: Verbruggen, Lise, et al.
Publicado: (2023)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma
por: Grogan, Alexander, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Real‐world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma
por: Wang, Chao, et al.
Publicado: (2022)

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
por: Barzi, Afsaneh, et al.
Publicado: (2020)

Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases
por: DeBusk, Kendra, et al.
Publicado: (2022)

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma
por: Pérez-Mancera, Pedro A., et al.
Publicado: (2012)

ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma
por: Oria, Victor O., et al.
Publicado: (2019)

Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels
por: Seifert, Adrian M., et al.
Publicado: (2020)

Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma
por: Matsushita, Katsunori, et al.
Publicado: (2021)

A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
por: Wang, Yi, et al.
Publicado: (2018)

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
por: Raj, Deepak, et al.
Publicado: (2019)

Estimating Metastatic Risk of Pancreatic Ductal Adenocarcinoma at Single-Cell Resolution
por: Chen, Sina, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma in colonic wall: metastatic disease or cancerized pancreatic ectopic tissue?
por: Gallo, Graziana, et al.
Publicado: (2020)

The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma
por: Xu, Peng, et al.
Publicado: (2021)

Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data
por: Tang, Hui, et al.
Publicado: (2022)

CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation
por: Wlodarczyk, Barbara, et al.
Publicado: (2023)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_agdbvfdhjr8rklmkc4mcu2os77